95 related articles for article (PubMed ID: 11176979)
1. Histological effects in the iris after 3 months of latanoprost therapy: the Mainz 1 study.
Pfeiffer N; Grierson I; Goldsmith H; Hochgesand D; Winkgen-Böhres A; Appleton P
Arch Ophthalmol; 2001 Feb; 119(2):191-6. PubMed ID: 11176979
[TBL] [Abstract][Full Text] [Related]
2. Fine structural evaluation of the iris after unilateral treatment with latanoprost in patients undergoing bilateral trabeculectomy (the Mainz II study).
Pfeiffer N; Grierson I; Goldsmith H; Appleton P; Hochgesand D; Winkgen A
Arch Ophthalmol; 2003 Jan; 121(1):23-31. PubMed ID: 12523881
[TBL] [Abstract][Full Text] [Related]
3. A 5-year, multicenter, open-label, safety study of adjunctive latanoprost therapy for glaucoma.
Alm A; Schoenfelder J; McDermott J
Arch Ophthalmol; 2004 Jul; 122(7):957-65. PubMed ID: 15249358
[TBL] [Abstract][Full Text] [Related]
4. Latanoprost-induced iris heterochromia and open-angle glaucoma: a clinicopathologic report.
Tsai JC; Sivak-Callcott JA; Haik BG; Zhang J; McLean IW
J Glaucoma; 2001 Oct; 10(5):411-3. PubMed ID: 11711840
[TBL] [Abstract][Full Text] [Related]
5. Morphometric effects of long-term exposure to latanoprost.
Cracknell KP; Grierson I; Hogg P
Ophthalmology; 2007 May; 114(5):938-48. PubMed ID: 17292473
[TBL] [Abstract][Full Text] [Related]
6. A study of iridectomy histopathologic features of latanoprost- and non-latanoprost-treated patients.
Albert DM; Gangnon RE; Zimbric ML; Damico CM; Fisher MR; Gleiser J; Grossniklaus HE; Green WR
Arch Ophthalmol; 2004 Nov; 122(11):1680-5. PubMed ID: 15534130
[TBL] [Abstract][Full Text] [Related]
7. Latanoprost-induced changes in the iris and trabeculum: an electron-microscopic morphological study.
Yildirim N; Sahin A; Kara S; Baycu C
Int Ophthalmol; 2010 Feb; 30(1):93-7. PubMed ID: 19139827
[TBL] [Abstract][Full Text] [Related]
8. A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma.
Mastropasqua L; Carpineto P; Ciancaglini M; Gallenga PE
Ophthalmology; 1999 Mar; 106(3):550-5. PubMed ID: 10080213
[TBL] [Abstract][Full Text] [Related]
9. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
[TBL] [Abstract][Full Text] [Related]
10. Latanoprost-induced iris darkening: a morphometric study of human peripheral iridectomies.
Cracknell KP; Grierson I; Hogg P; Appleton P; Pfeiffer N
Exp Eye Res; 2003 Dec; 77(6):721-30. PubMed ID: 14609560
[TBL] [Abstract][Full Text] [Related]
11. Quality of diurnal intraocular pressure control in primary open-angle patients treated with latanoprost compared with surgically treated glaucoma patients: a prospective trial.
Mansouri K; Orguel S; Mermoud A; Haefliger I; Flammer J; Ravinet E; Shaarawy T
Br J Ophthalmol; 2008 Mar; 92(3):332-6. PubMed ID: 18211927
[TBL] [Abstract][Full Text] [Related]
12. The influence of topical diclofenac sodium on the ocular hypotensive effect of latanoprost in glaucoma patients.
Sorkhabi R; Alipanahi R; Eftakhari-Milani A; Ghojazadeh L
J Glaucoma; 2011; 20(4):240-3. PubMed ID: 20577116
[TBL] [Abstract][Full Text] [Related]
13. Comparison of intraocular pressure in glaucoma subjects treated with Xalatan versus generic latanoprost.
Egan P; Harris A; Siesky B; Abrams-Tobe L; Gerber AL; Park J; Holland S; Kim NJ; Januleviciene I
Acta Ophthalmol; 2014 Aug; 92(5):e415-6. PubMed ID: 24373426
[No Abstract] [Full Text] [Related]
14. The effect of latanoprost on aqueous humor PGF2alpha levels in glaucoma patients.
Güven D; Karakurt A; Saban E; Hasiripi H
Int Ophthalmol; 1999; 23(2):91-6. PubMed ID: 11196126
[TBL] [Abstract][Full Text] [Related]
15. Effect of treatment by medicine or surgery on intraocular pressure and pulsatile ocular blood flow in normal-pressure glaucoma.
Poinoosawmy D; Indar A; Bunce C; Garway-Heath DF; Hitchings RA
Graefes Arch Clin Exp Ophthalmol; 2002 Sep; 240(9):721-6. PubMed ID: 12271368
[TBL] [Abstract][Full Text] [Related]
16. Analysis of irises with a latanoprost-induced change in iris color.
Arranz-Marquez E; Teus MA; Saornil MA; Mendez MC; Gil R
Am J Ophthalmol; 2004 Oct; 138(4):625-30. PubMed ID: 15488791
[TBL] [Abstract][Full Text] [Related]
17. Intraocular pressure-lowering effects of latanoprost monotherapy versus latanoprost or pilocarpine in combination with timolol: a randomized, observer-masked multicenter study in patients with open-angle glaucoma. Italian Latanoprost Study Group.
Bucci MG
J Glaucoma; 1999 Feb; 8(1):24-30. PubMed ID: 10084271
[TBL] [Abstract][Full Text] [Related]
18. The influence of diclofenac ophthalmic solution on the intraocular pressure-lowering effect of topical 0.5% timolol and 0.005% latanoprost in primary open-angle glaucoma patients.
Costagliola C; Parmeggiani F; Antinozzi PP; Caccavale A; Cotticelli L; Sebastiani A
Exp Eye Res; 2005 Nov; 81(5):610-5. PubMed ID: 15949795
[TBL] [Abstract][Full Text] [Related]
19. Diurnal intraocular pressure reduction with latanoprost 0.005% compared to timolol maleate 0.5% as monotherapy in subjects with exfoliation glaucoma.
Konstas AG; Mylopoulos N; Karabatsas CH; Kozobolis VP; Diafas S; Papapanos P; Georgiadis N; Stewart WC
Eye (Lond); 2004 Sep; 18(9):893-9. PubMed ID: 15002024
[TBL] [Abstract][Full Text] [Related]
20. Incidence of a latanoprost-induced increase in iris pigmentation in Japanese eyes.
Latanoprost-Induced Iris Pigmentation Study Group
Jpn J Ophthalmol; 2006; 50(2):96-9. PubMed ID: 16604382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
